Chronic Hepatitis B Virus
Bluejay Therapeutics’ brelovitug secures FDA breakthrough status for chronic HDV
The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the company announced in a press release.
HCV elimination efforts in Georgia lower infections by 61%, may advance reaching 2030 goal
A hepatitis C elimination program in Georgia reduced the estimated annual incidence of new infections by 61% since its launch in April 2015, which may accelerate efforts to reach the global 2030 elimination goal.
Adjuvanted hepatitis B vaccine effective among nonresponsive HCWs
A two-dose series of a hepatitis B vaccine with a CpG adjuvant resulted in a more than 90% response rate among health care workers previously classified as nonresponders, researchers found.
Older age, high HBsAg levels linked to increased risk for flare after treatment withdrawal
Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress.
VIDEO: Prevention ‘always better than a cure’ for hepatitis B virus infection
In a Healio video exclusive, Jeff Baxter, president and CEO of VBI Vaccines, discusses the current burden of hepatitis B virus infection and shares updates on prevention and treatment strategies for Hepatitis Awareness Month.
Antiviral activity of VIR-2218 boosted by immunomodulators in treatment of chronic HBV
WASHINGTON — Pegylated interferon alpha potentiated the antiviral activity of VIR-2218 in a small subset of noncirrhotic patients with chronic hepatitis B, according to preliminary data presented at The Liver Meeting.
Antiviral combination plus standard therapy achieves ‘controlled biological state’ in HBV
LONDON — Therapy combining small interfering RNA, capsid assembly modulator and nucleotide analogue reduced HBsAg levels over 24 weeks compared with standard therapy, according to a presenter at the International Liver Congress.
VIDEO: Expert emphasizes screening, vaccination to control hepatitis
May 19 is Hepatitis Testing Day, and in this Healio video exclusive, Nancy S. Reau, MD, FAASLD, AGAF, stresses the importance of screening and vaccination to reach global hepatitis elimination.
Q&A: HIV links to diminished control of HBV coinfection
Novel hepatitis B virus RNA and HBV core-related antigen blood assays revealed continued disease activity despite apparently suppressed virus replication among patients dosed with antiviral therapy for HBV and HIV coinfection.
With rising HBV burden, experts say it is critical to implement new vaccine guideline
The CDC’s Advisory Committee on Immunization Practices recently issued a universal recommendation that all adults aged 19 to 59 years receive the hepatitis B vaccine.